Figure 3.

Effect of ronacaleret on the plasma glucose, insulin, and glucagon concentrations of male mice during IPGTT. Ronacaleret administration had no effect on the plasma glucose concentrations of (a) Casr^+/+ mice (black dashed line) but significantly lowered plasma glucose in (b) Casr^Nuf/+ (blue dashed line) and (c) Casr^Nuf/Nuf mice (red dashed line) compared with respective control mice treated with the drug vehicle only (represented by solid lines), so that the glucose concentrations were not significantly different from Casr^+/+ mice. Ronacaleret had no effect on the plasma insulin concentrations of (d) Casr^+/+ mice but significantly increased plasma insulin in (e) Casr^Nuf/+ mice compared with controls, so that the insulin concentrations were not significantly different from Casr^+/+ mice. Ronacaleret treatment did not alter plasma insulin concentrations in (f) Casr^Nuf/Nuf mice. Ronacaleret had no significant effect on the plasma glucagon concentrations of (g) Casr^+/+ mice, (h) Casr^Nuf/+ mice, or (i) Casr^Nuf/Nuf mice compared with respective control mice. Results are expressed as mean ± standard error of the mean. *P < 0.05, **P < 0.01 compared with control mice.